Medivir in media

Regulus rises on HCV data

Regulus Therapeutics Inc. (NASDAQ:RGLS) gained $1.21 (19%) to $7.49 on Wednesday after reporting interim data from a Phase II trial of a four-week regimen of RG-101 plus a once-daily ...

Source: BioCentury - The Daily Extra 18 Feb 2016 03:51
Janssen-Cilag International NV ) Presents New Data Assessing OLYSIO (Simeprevir) In Combination With Sofosbuvir In Genotype 4 Infected HCV Patients In Egypt

BEERSE, Belgium--( BUSINESS WIRE )--Janssen-Cilag International NV (Janssen) today announced the preliminary results from the Phase IIa OSIRIS trial, at the Liver Meeting ®, the Annual ...

Source: BioSpace - News 16 Nov 2015 21:06
Medivir to merge Research and Development and implement changes within the management group

STOCKHOLM, Sweden--( BUSINESS WIRE )-- Medivir AB (Nasdaq Stockholm: MVIR) (STO:MVIRB) today announces that, as the next step in the company's optimisation process, its research ...

Source: BioMedReports 16 Sep 2015 14:08
Stock Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Enters Into Worldwide Collaboration for Hepatitis C With Janssen

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ) announced today that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. (Janssen), one ...

Source: Smarter Analyst - Stock News 19 May 2015 22:15
Newer HCV Agents Mostly Cost-Effective

But increased demand for direct-acting drugs could break the healthcare bank.

Source: MedPage Today - Gastroenterology 16 Mar 2015 22:09
Medivir's Nomination Committee proposes new Board of Directors ahead of 2015 AGM

Medivir AB (OMX: MVIR) today announced the Nomination Committee's proposal for a new Board of Directors that will be submitted to the 2015 Annual General Meeting. The 2014-2015 ...

Source: iStock Analyst - Press Releases 18 Feb 2015 10:02
NICE Recommends Janssen's Olysio for Hepatitis C Genotype 1 and 4

The UK's health cost-benefit watchdog is recommending coverage of Janssen's drug Olysio as a treatment option for people with both genotype 1 and genotype 4 hepatitis C.

Source: FDA News - FDAnews Drug Daily Bulletin 23 Jan 2015 22:54
Clinical setbacks integral to long-term success in HCV treatment

In a new report, the Pharmaceutical Research and Manufacturers of America examined the successes and failures of hepatitis C virus infection research and therapies since the infection was ...

Source: HemOnc Today - Hepatology 19 Dec 2014 19:12
Simeprevir with PEG-IFN a-2a/Ribavirin Safely Treated HCV

In a new study, treatment with simeprevir and a combination of pegylated interferon alfa-2a and ribavirin yielded noninferior response rates to treatment with telaprevir among patients with ...

Source: HemOnc Today 11 Dec 2014 21:30

 

RSS updated 0 minutes ago.

Page updated 17 April 2015